NYSE:MNK - Mallinckrodt Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.45 +0.01 (+0.06 %)
(As of 05/25/2018 12:49 PM ET)
Previous Close$16.44
Today's Range$16.28 - $16.59
52-Week Range$11.65 - $49.12
Volume843,672 shs
Average Volume3.78 million shs
Market Capitalization$1.36 billion
P/E Ratio2.20
Dividend YieldN/A
Beta1.13

About Mallinckrodt (NYSE:MNK)

Mallinckrodt logoMallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:MNK
CUSIPN/A
Phone44-0-17-8463-6700

Debt

Debt-to-Equity Ratio1.00
Current Ratio2.10
Quick Ratio1.90

Price-To-Earnings

Trailing P/E Ratio2.20
Forward P/E Ratio2.63
P/E Growth0.27

Sales & Book Value

Annual Sales$3.22 billion
Price / Sales0.42
Cash Flow$16.2871 per share
Price / Cash1.01
Book Value$77.77 per share
Price / Book0.21

Profitability

EPS (Most Recent Fiscal Year)$7.49
Net Income$2.13 billion
Net Margins57.56%
Return on Equity11.59%
Return on Assets4.48%

Miscellaneous

Employees3,900
Outstanding Shares83,080,000

Mallinckrodt (NYSE:MNK) Frequently Asked Questions

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt's stock buyback program work?

Mallinckrodt declared that its board has authorized a stock repurchase plan on Sunday, April 9th 2017, which permits the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy up to 18.5% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board of directors believes its stock is undervalued.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) released its earnings results on Tuesday, May, 8th. The company reported $1.31 EPS for the quarter, topping the Zacks' consensus estimate of $1.08 by $0.23. The business earned $572.60 million during the quarter, compared to the consensus estimate of $568.78 million. Mallinckrodt had a net margin of 57.56% and a return on equity of 11.59%. The firm's quarterly revenue was up 2.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.04 earnings per share. View Mallinckrodt's Earnings History.

When is Mallinckrodt's next earnings date?

Mallinckrodt is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Mallinckrodt.

What guidance has Mallinckrodt issued on next quarter's earnings?

Mallinckrodt updated its FY earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of $6.00-6.50 for the period, compared to the Thomson Reuters consensus estimate of $7.14. The company issued revenue guidance of +3-6% to ~$.

What price target have analysts set for MNK?

19 Wall Street analysts have issued 1-year price objectives for Mallinckrodt's shares. Their predictions range from $12.00 to $67.00. On average, they anticipate Mallinckrodt's stock price to reach $31.2632 in the next year. View Analyst Ratings for Mallinckrodt.

What are Wall Street analysts saying about Mallinckrodt stock?

Here are some recent quotes from research analysts about Mallinckrodt stock:
  • 1. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis: 1) YTD (today), total debt has decreased by roughly ~$215MM. the end of 1Q18 was 4.6x, an expected increase from last quarter, following the close of the SCMP deal., 2) MNK presented its free cash flow guidance for the first time. This is expected to be ~$0.5B in 2018. Operating cash flow in 1Q18 of ~$18MM was impacted primarily by assumed liabilities paid following the close of the SCMP transaction. MNK expects free cash flow to return to more normal levels the remainder of the year., 3) While debt reduction is MNK’s top priority with respect to capital allocation for 2018, MNK did repurchase 2.9MM shares in 1Q18." (5/8/2018)
  • 2. Mizuho analysts commented, "We plan to remove all risk-adjusted estimates for this compound from our model after the earnings call, which will be somewhat offset by the greater than $0.15-$0.20 in dilution to adjusted earnings expected in 2018″." (5/3/2018)
  • 3. According to Zacks Investment Research, "Mallinckrodt is selling its hemostasis products for Baxter. The company aims to focus better on its specialty pharmaceutical business after having sold its Nuclear Imaging business.Mallinckrodt is facing challenging conditions as lead drug Acthar sales declined on volume while weaknesses in the generics segment persist. Acthar declined as specialty drugs face payer environment and the decline is expected to continue in the fourth quarter as well. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Shares of the company have underperformed the industry in the last six months. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax.  As  a result, Mallinckrodt is looking to diversify its portfolio with the recently announced Sucampo acquisition and counter the decline in existing drugs." (1/9/2018)

Who are some of Mallinckrodt's key competitors?

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the folowing people:
  • Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 57)
  • Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 48)
  • Dr. Frank Scholz, Exec. VP of Global Operations & Pres of Specialty Generics (Age 49)
  • Mr. Hugh M. O'Neill, Exec. VP and Pres of Autoimmune & Rare Diseases (Age 55)
  • Dr. Gary M. Phillips, Exec. VP & Chief Strategy Officer (Age 52)

Has Mallinckrodt been receiving favorable news coverage?

Headlines about MNK stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mallinckrodt earned a coverage optimism score of 0.07 on Accern's scale. They also gave media stories about the company an impact score of 46.56 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Mallinckrodt's major shareholders?

Mallinckrodt's stock is owned by a number of of institutional and retail investors. Top institutional investors include Scopia Capital Management LP (10.38%), BlackRock Inc. (9.38%), Dimensional Fund Advisors LP (4.91%), LSV Asset Management (3.04%), Robeco Institutional Asset Management B.V. (1.66%) and Millennium Management LLC (1.30%). Company insiders that own Mallinckrodt stock include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, James E Flynn, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt.

Which institutional investors are selling Mallinckrodt stock?

MNK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Schroder Investment Management Group, Prudential Financial Inc., Legal & General Group Plc, State of Wisconsin Investment Board, Allianz Asset Management GmbH, Allianz Asset Management GmbH and A.R.T. Advisors LLC. View Insider Buying and Selling for Mallinckrodt.

Which institutional investors are buying Mallinckrodt stock?

MNK stock was purchased by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Millennium Management LLC, Robeco Institutional Asset Management B.V., Dimensional Fund Advisors LP, Neuberger Berman Group LLC, UBS Group AG, Engineers Gate Manager LP and Seven Eight Capital LP. Company insiders that have bought Mallinckrodt stock in the last two years include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt.

How do I buy shares of Mallinckrodt?

Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $16.45.

How big of a company is Mallinckrodt?

Mallinckrodt has a market capitalization of $1.36 billion and generates $3.22 billion in revenue each year. The company earns $2.13 billion in net income (profit) each year or $7.49 on an earnings per share basis. Mallinckrodt employs 3,900 workers across the globe.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]


MarketBeat Community Rating for Mallinckrodt (MNK)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  629 (Vote Outperform)
Underperform Votes:  381 (Vote Underperform)
Total Votes:  1,010
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mallinckrodt (NYSE:MNK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Mallinckrodt in the last 12 months. Their average twelve-month price target is $31.2632, suggesting that the stock has a possible upside of 90.05%. The high price target for MNK is $67.00 and the low price target for MNK is $12.00. There are currently 1 sell rating, 13 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.212.222.332.42
Ratings Breakdown: 1 Sell Rating(s)
13 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
12 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.2632$33.8333$42.6389$47.9737
Price Target Upside: 90.05% upside157.68% upside134.93% upside126.08% upside

Mallinckrodt (NYSE:MNK) Consensus Price Target History

Price Target History for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE:MNK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018OppenheimerReiterated RatingHoldLowView Rating Details
5/9/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$27.00 ➝ $14.00HighView Rating Details
5/9/2018BarclaysSet Price TargetUnderweight ➝ Underweight$20.00 ➝ $12.00HighView Rating Details
5/8/2018Canaccord GenuitySet Price TargetHold$14.00HighView Rating Details
5/8/2018Cantor FitzgeraldReiterated RatingBuy$42.00MediumView Rating Details
5/4/2018Wells Fargo & CoSet Price TargetHold$17.50 ➝ $15.00LowView Rating Details
5/3/2018MizuhoReiterated RatingHold$15.00MediumView Rating Details
5/2/2018B. RileyInitiated CoverageNeutral ➝ Neutral$15.00 ➝ $15.00LowView Rating Details
4/23/2018Leerink SwannLower Price TargetMarket PerformLowView Rating Details
4/12/2018Stifel NicolausDowngradeBuy ➝ Hold$50.00HighView Rating Details
4/11/2018SunTrust BanksInitiated CoverageHold$15.00HighView Rating Details
1/1/2018Goldman Sachs GroupReiterated RatingHoldHighView Rating Details
11/26/2017UBSDowngradeBuy ➝ Neutral$70.00 ➝ $24.00MediumView Rating Details
11/8/2017BMO Capital MarketsLower Price TargetOutperform$38.00N/AView Rating Details
11/8/2017Jefferies GroupInitiated CoverageMarket Perform ➝ Buy$60.00 ➝ $30.00N/AView Rating Details
11/7/2017CitigroupDowngradeBuy ➝ Hold$44.00 ➝ $28.00N/AView Rating Details
11/7/2017Deutsche BankDowngradeBuy ➝ Hold$44.00 ➝ $28.00N/AView Rating Details
10/21/2017Piper Jaffray CompaniesSet Price TargetBuy$67.00N/AView Rating Details
8/9/2017Raymond JamesLower Price TargetOutperform$65.00 ➝ $58.00LowView Rating Details
4/1/2017GuggenheimSet Price TargetBuy$98.00LowView Rating Details
1/25/2017JPMorgan Chase & Co.Set Price TargetHold$78.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Mallinckrodt (NYSE:MNK) Earnings History and Estimates Chart

Earnings by Quarter for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE:MNK) Earnings Estimates

2018 EPS Consensus Estimate: $6.09
2019 EPS Consensus Estimate: $5.24
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$1.08$1.55$1.21
Q2 20186$1.37$1.65$1.52
Q3 20186$1.57$1.75$1.66
Q4 20186$1.50$1.85$1.71
Q1 20191$1.10$1.10$1.10
Q2 20191$1.41$1.41$1.41
Q3 20191$1.41$1.41$1.41
Q4 20191$1.32$1.32$1.32

Mallinckrodt (NYSE MNK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
5/8/2018Q1 2018$1.08$1.31$568.78 million$572.60 millionViewN/AView Earnings Details
2/27/2018Q4 2017$1.72$2.01$769.91 million$792.30 millionViewListenView Earnings Details
11/7/2017Q3 2017$1.80$1.97$808.93 million$793.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017$1.73$1.85$829.56 million$824.50 millionViewListenView Earnings Details
5/8/2017Q1 2017$1.63$1.68$781.23 million$810.90 millionViewListenView Earnings Details
2/7/2017Q117$1.82$1.91$827.12 million$829.90 millionViewListenView Earnings Details
11/29/2016Q416$1.98$2.04$880.10 million$887.20 millionViewListenView Earnings Details
8/2/2016Q316$2.01$2.20$920.35 million$970.60 millionViewListenView Earnings Details
5/3/2016Q216$1.72$2.01$878.70 million$918.00 millionViewListenView Earnings Details
2/2/2016Q116$1.78$2.09$888.33 million$915.00 millionViewListenView Earnings Details
11/23/2015Q415$1.77$1.84$869.41 million$882.40 millionViewListenView Earnings Details
8/4/2015Q315$1.82$2.05$983.81 million$965.10 millionViewListenView Earnings Details
5/5/2015Q215$1.48$1.72$860.89 million$909.90 millionViewListenView Earnings Details
2/3/2015Q115$1.57$1.84$880.12 million$866.00 millionViewListenView Earnings Details
11/19/2014Q414$1.41$1.68$759.04 million$789.00 millionViewListenView Earnings Details
8/7/2014Q314$0.86$1.20$278.80 million$653.10 millionViewListenView Earnings Details
5/8/2014Q214$0.79$0.95$566.50 million$557.80 millionViewListenView Earnings Details
2/6/2014Q1$0.66$0.88$539.24 million$540.20 millionViewListenView Earnings Details
11/7/2013$0.85$1.02$572.57 million$552.20 millionViewListenView Earnings Details
8/9/2013Q3 2013$0.78$0.49$557.22 million$570.00 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Mallinckrodt (NYSE:MNK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Mallinckrodt (NYSE MNK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.80%
Insider Trading History for Mallinckrodt (NYSE:MNK)
Institutional Ownership by Quarter for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE MNK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2018Mark TrudeauInsiderBuy3,000$15.54$46,620.00View SEC Filing  
5/9/2018James E FlynnInsiderSell312,928$13.39$4,190,105.92View SEC Filing  
11/28/2017Dr Kneeland YoungbloodDirectorBuy4,560$21.94$100,046.4019,789View SEC Filing  
11/13/2017Joann A ReedDirectorBuy1,000$21.50$21,500.0015,554View SEC Filing  
11/13/2017Steven J. RomanoVPBuy2,000$21.96$43,920.00View SEC Filing  
11/10/2017Mark TrudeauCEOBuy5,000$22.28$111,400.00View SEC Filing  
11/9/2017David R CarlucciDirectorBuy10,000$21.83$218,300.0026,020View SEC Filing  
11/9/2017Michael-Bryant HicksGeneral CounselBuy7,900$20.80$164,320.00View SEC Filing  
8/30/2017Meredith B. FischerInsiderBuy1,280$39.63$50,726.40View SEC Filing  
6/9/2017Steven J. RomanoVPBuy1,000$39.88$39,880.00View SEC Filing  
6/8/2017Hugh M. O'neillVPBuy1,000$40.24$40,240.00View SEC Filing  
6/5/2017Coleman N Lannum IIIVPBuy500$39.33$19,665.0031,455View SEC Filing  
6/2/2017Coleman N Lannum IIIVPBuy1,350$42.89$57,901.5030,955View SEC Filing  
5/12/2017Coleman N. Lannum IIIVPBuy1,968$46.20$90,921.60View SEC Filing  
3/10/2017Matthew K. HarbaughCFOBuy600$49.19$29,514.00View SEC Filing  
3/7/2017Michael-Bryant HicksGeneral CounselBuy290$50.35$14,601.50View SEC Filing  
2/23/2017Meredith B. FischerInsiderBuy2,000$54.34$108,680.00View SEC Filing  
2/14/2017Mark TrudeauInsiderBuy1,000$50.47$50,470.00View SEC Filing  
2/10/2017Steven J. RomanoVPBuy1,000$49.68$49,680.00View SEC Filing  
5/10/2016Hugh M O'neillVPBuy1,653$60.99$100,816.4715,623View SEC Filing  
5/10/2016Matthew K HarbaughCFOBuy500$59.37$29,685.0056,036View SEC Filing  
5/6/2016Mark TrudeauCEOBuy1,000$56.02$56,020.00192,546View SEC Filing  
5/6/2016Steven J RomanoVPBuy900$56.00$50,400.009,291View SEC Filing  
3/4/2016Coleman N Lannum IIIVPBuy2,600$62.63$162,838.0020,556View SEC Filing  
2/26/2016Meredith B FischerVPBuy1,400$69.80$97,720.0017,643View SEC Filing  
2/12/2016Coleman N Lannum IIIVPBuy600$59.66$35,796.0017,940View SEC Filing  
2/10/2016Coleman N Lannum IIIVPBuy1,300$62.58$81,354.0017,340View SEC Filing  
2/9/2016Matthew K. HarbaughCFOBuy1,300$63.00$81,900.00View SEC Filing  
2/8/2016Coleman N. Lannum IIIVPBuy800$66.37$53,096.00View SEC Filing  
12/22/2015Coleman N Lannum IIISVPBuy500$72.50$36,250.0011,266View SEC Filing  
12/11/2015Terrance L CarlsonGeneral CounselBuy1,000$69.10$69,100.002,549View SEC Filing  
12/2/2015Gary M. PhillipsVPBuy1,000$72.17$72,170.007,728View SEC Filing  
11/30/2015Mark TrudeauCEOBuy1,350$65.89$88,951.50167,526View SEC Filing  
11/27/2015Coleman N Lannum IIISVPBuy1,200$66.86$80,232.009,986View SEC Filing  
11/27/2015Meredith B FischerVPBuy2,200$66.93$147,246.0014,280View SEC Filing  
11/27/2015Terrance L CarlsonGeneral CounselBuy1,000$66.54$66,540.001,453View SEC Filing  
8/25/2015Hugh M O'neillSVPBuy1,197$83.52$99,973.449,015View SEC Filing  
8/25/2015Mark TrudeauCEOBuy1,000$83.08$83,080.00166,176View SEC Filing  
8/21/2015Coleman N Lannum IIISVPBuy2,375$88.52$210,235.007,361View SEC Filing  
8/21/2015Mark TrudeauCEOBuy2,000$88.45$176,900.00165,176View SEC Filing  
6/4/2015Coleman N Lannum IIIVPBuy1,300$126.41$164,333.00View SEC Filing  
6/2/2015Matthew K HarbaughCFOSell22,106$128.64$2,843,715.84View SEC Filing  
5/18/2015Mario D SaltarelliVPSell4,580$127.44$583,675.20View SEC Filing  
5/13/2015Don M BaileyDirectorSell51,417$122.45$6,296,011.65View SEC Filing  
5/11/2015Sandra L HattenVPSell2,024$122.29$247,514.96View SEC Filing  
4/13/2015Don M BaileyDirectorSell40,000$127.61$5,104,400.00View SEC Filing  
3/13/2015Don M BaileyDirectorSell40,000$123.40$4,936,000.00View SEC Filing  
2/13/2015Don M BaileyDirectorSell33,891$114.63$3,884,925.33View SEC Filing  
2/2/2015Mark TrudeauCEOSell11,925$105.94$1,263,334.50View SEC Filing  
1/9/2015Mark TrudeauCEOSell15,720$102.00$1,603,440.00View SEC Filing  
12/22/2014Peter G EdwardsVPSell1,265$99.69$126,107.85View SEC Filing  
12/18/2014Mark TrudeauCEOSell13,831$93.59$1,294,443.29View SEC Filing  
9/10/2014Raymond J FureyVPSell5,441$85.90$467,381.90View SEC Filing  
9/8/2014Don M BaileyDirectorSell221,177$85.23$18,850,915.71View SEC Filing  
9/5/2014Raymond J FureyVPSell15,000$85.47$1,282,050.00View SEC Filing  
9/5/2014Virgil D ThompsonDirectorSell25,000$83.76$2,094,000.00View SEC Filing  
9/2/2014Raymond J FureyVPSell10,303$81.61$840,827.83View SEC Filing  
8/29/2014Raymond J FureyVPSell4,840$80.90$391,556.00View SEC Filing  
8/19/2014Joseph A ZaccagninoDirectorBuy3,000$71.06$213,180.00View SEC Filing  
8/13/2014Paulson & Co IncMajor ShareholderBuy132,100$69.80$9,220,580.00View SEC Filing  
8/12/2014J Martin CarrollDirectorBuy2,000$69.24$138,480.00View SEC Filing  
8/12/2014Paulson & Co IncMajor ShareholderBuy467,900$68.78$32,182,162.00View SEC Filing  
8/11/2014Paulson & Co IncMajor ShareholderBuy207,900$69.70$14,490,630.00View SEC Filing  
8/7/2014Paulson & Co IncMajor ShareholderBuy700,200$70.15$49,119,030.00View SEC Filing  
8/1/2014Paulson & Co IncMajor ShareholderBuy275,000$69.60$19,140,000.00View SEC Filing  
6/11/2014Melvin D BoothDirectorBuy4,000$76.05$304,200.00View SEC Filing  
5/9/2014Paulson & Co Incmajor shareholderBuy786,207$73.63$57,888,421.41View SEC Filing  
2/3/2014Mark TrudeauCEOSell14,890$56.12$835,626.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mallinckrodt (NYSE MNK) News Headlines

Source:
DateHeadline
Mallinckrodt PLC (MNK) Given Average Recommendation of "Hold" by AnalystsMallinckrodt PLC (MNK) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 25 at 5:34 AM
Equities Analysts Issue Forecasts for Mallinckrodt PLCs FY2018 Earnings (MNK)Equities Analysts Issue Forecasts for Mallinckrodt PLC's FY2018 Earnings (MNK)
www.americanbankingnews.com - May 24 at 8:36 AM
Mallinckrodt (MNK) Insider Mark Trudeau Purchases 3,000 SharesMallinckrodt (MNK) Insider Mark Trudeau Purchases 3,000 Shares
www.americanbankingnews.com - May 18 at 8:35 PM
Appeals court nixes Mallinckrodt patent on respiratory treatmentAppeals court nixes Mallinckrodt patent on respiratory treatment
www.reuters.com - May 18 at 9:07 AM
Q2 2018 EPS Estimates for Mallinckrodt Lifted by B. Riley (MNK)Q2 2018 EPS Estimates for Mallinckrodt Lifted by B. Riley (MNK)
www.americanbankingnews.com - May 18 at 7:16 AM
Mallinckrodt Forecasted to Earn Q2 2018 Earnings of $1.37 Per Share (MNK)Mallinckrodt Forecasted to Earn Q2 2018 Earnings of $1.37 Per Share (MNK)
www.americanbankingnews.com - May 18 at 7:13 AM
Mallinckrodt (MNK) Expected to Announce Quarterly Sales of $621.54 MillionMallinckrodt (MNK) Expected to Announce Quarterly Sales of $621.54 Million
www.americanbankingnews.com - May 18 at 2:02 AM
Mallinckrodt: Appeals Court Rules Inomax Patent InvalidMallinckrodt: Appeals Court Rules Inomax Patent Invalid
seekingalpha.com - May 17 at 5:53 PM
BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen BusinessBioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business
finance.yahoo.com - May 17 at 8:47 AM
Zacks: Analysts Anticipate Mallinckrodt (MNK) to Post $1.54 Earnings Per ShareZacks: Analysts Anticipate Mallinckrodt (MNK) to Post $1.54 Earnings Per Share
www.americanbankingnews.com - May 16 at 7:10 PM
Mallinckrodts (MNK) "Hold" Rating Reiterated at OppenheimerMallinckrodt's (MNK) "Hold" Rating Reiterated at Oppenheimer
www.americanbankingnews.com - May 16 at 3:40 PM
Mallinckrodt: Acthar Continues To CrackMallinckrodt: Acthar Continues To Crack
seekingalpha.com - May 15 at 5:33 PM
Mallinckrodt To Present At Goldman Sachs 39th Annual Global Healthcare ConferenceMallinckrodt To Present At Goldman Sachs 39th Annual Global Healthcare Conference
finance.yahoo.com - May 14 at 5:07 PM
Q4 2018 EPS Estimates for Mallinckrodt Cut by SunTrust Banks (MNK)Q4 2018 EPS Estimates for Mallinckrodt Cut by SunTrust Banks (MNK)
www.americanbankingnews.com - May 14 at 4:03 AM
Mallinckrodt Forecasted to Earn Q2 2018 Earnings of $1.48 Per Share (MNK)Mallinckrodt Forecasted to Earn Q2 2018 Earnings of $1.48 Per Share (MNK)
www.americanbankingnews.com - May 14 at 2:15 AM
Leerink Swann Comments on Mallinckrodts Q4 2018 Earnings (MNK)Leerink Swann Comments on Mallinckrodt's Q4 2018 Earnings (MNK)
www.americanbankingnews.com - May 11 at 11:03 AM
Research Analysts Issue Forecasts for Mallinckrodts Q1 2019 Earnings (MNK)Research Analysts Issue Forecasts for Mallinckrodt's Q1 2019 Earnings (MNK)
www.americanbankingnews.com - May 11 at 11:02 AM
Q3 2018 Earnings Forecast for Mallinckrodt (MNK) Issued By SunTrust BanksQ3 2018 Earnings Forecast for Mallinckrodt (MNK) Issued By SunTrust Banks
www.americanbankingnews.com - May 11 at 10:15 AM
James E. Flynn Sells 312,928 Shares of Mallinckrodt (MNK) StockJames E. Flynn Sells 312,928 Shares of Mallinckrodt (MNK) Stock
www.americanbankingnews.com - May 10 at 7:22 PM
Hospital Product Sales Drive Mallinckrodt (MNK) Q1 EarningsHospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings
finance.yahoo.com - May 10 at 5:34 PM
Heres Why Mallinckrodt PLC Rose as Much as 16.3% TodayHere's Why Mallinckrodt PLC Rose as Much as 16.3% Today
www.fool.com - May 10 at 8:47 AM
Equities Analysts Set Expectations for Mallinckrodts Q2 2018 Earnings (MNK)Equities Analysts Set Expectations for Mallinckrodt's Q2 2018 Earnings (MNK)
www.americanbankingnews.com - May 10 at 7:04 AM
Q2 2018 EPS Estimates for Mallinckrodt (MNK) Cut by AnalystQ2 2018 EPS Estimates for Mallinckrodt (MNK) Cut by Analyst
www.americanbankingnews.com - May 10 at 6:45 AM
Mallinckrodt (MNK) to Post Q2 2018 Earnings of $1.51 Per Share, SunTrust Banks ForecastsMallinckrodt (MNK) to Post Q2 2018 Earnings of $1.51 Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - May 10 at 6:36 AM
Cantor Fitzgerald Remains Bullish on Mallinckrodt (MNK) Following 1QCantor Fitzgerald Remains Bullish on Mallinckrodt (MNK) Following 1Q
www.streetinsider.com - May 9 at 5:16 PM
Mallinckrodt: Why Im No Longer LongMallinckrodt: Why I'm No Longer Long
seekingalpha.com - May 9 at 5:16 PM
Here's Why Mallinckrodt PLC Rose as Much as 16.3% TodayHere's Why Mallinckrodt PLC Rose as Much as 16.3% Today
finance.yahoo.com - May 9 at 5:16 PM
Mallinckrodt (MNK) Price Target Lowered to $14.00 at Morgan StanleyMallinckrodt (MNK) Price Target Lowered to $14.00 at Morgan Stanley
www.americanbankingnews.com - May 9 at 4:53 PM
Mallinckrodt (MNK) Price Target Increased to $12.00 by Analysts at BarclaysMallinckrodt (MNK) Price Target Increased to $12.00 by Analysts at Barclays
www.americanbankingnews.com - May 9 at 1:29 PM
Mallinckrodt (MNK) PT Set at $14.00 by Canaccord GenuityMallinckrodt (MNK) PT Set at $14.00 by Canaccord Genuity
www.americanbankingnews.com - May 9 at 12:08 PM
Mallinckrodt plc (MNK) PT Lowered to $29 at BMO CapitalMallinckrodt plc (MNK) PT Lowered to $29 at BMO Capital
www.streetinsider.com - May 9 at 8:42 AM
Mallinckrodt Plc (MNK) Q1 2018 Results - Earnings Call TranscriptMallinckrodt Plc (MNK) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:42 AM
Edited Transcript of MNK earnings conference call or presentation 8-May-18 12:30pm GMTEdited Transcript of MNK earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 9 at 8:42 AM
Q3 2018 EPS Estimates for Mallinckrodt (MNK) Raised by AnalystQ3 2018 EPS Estimates for Mallinckrodt (MNK) Raised by Analyst
www.americanbankingnews.com - May 9 at 7:56 AM
Form 8-K Mallinckrodt plc For: May 08Form 8-K Mallinckrodt plc For: May 08
www.streetinsider.com - May 8 at 5:17 PM
Cantor Fitzgerald Reiterates "$42.00" Price Target for Mallinckrodt (MNK)Cantor Fitzgerald Reiterates "$42.00" Price Target for Mallinckrodt (MNK)
www.americanbankingnews.com - May 8 at 3:28 PM
Mallinckrodt (MNK) Issues Quarterly  Earnings ResultsMallinckrodt (MNK) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 11:52 AM
Earnings Reaction History: Mallinckrodt plc, 70.0% Follow-Through Indicator, 10.1% SensitiveEarnings Reaction History: Mallinckrodt plc, 70.0% Follow-Through Indicator, 10.1% Sensitive
www.nasdaq.com - May 8 at 8:36 AM
Mallinckrodt (MNK) Tops Q1 EPS by 22c, Beats on RevenuesMallinckrodt (MNK) Tops Q1 EPS by 22c, Beats on Revenues
www.streetinsider.com - May 8 at 8:36 AM
BRIEF-Mallinckrodt Reports Q1 Adjusted Earnings Per Share Of $1.31BRIEF-Mallinckrodt Reports Q1 Adjusted Earnings Per Share Of $1.31
www.reuters.com - May 8 at 8:36 AM
Mallinckrodt plc Reports First Quarter 2018 ResultsMallinckrodt plc Reports First Quarter 2018 Results
finance.yahoo.com - May 8 at 8:36 AM
Mallinckrodt: 1Q Earnings SnapshotMallinckrodt: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:36 AM
Mallinckrodt Provides Facts on HP Acthar® GelMallinckrodt Provides Facts on HP Acthar® Gel
www.prnewswire.com - May 7 at 8:37 AM
Mallinckrodt Provides Facts on H.P. Acthar® GelMallinckrodt Provides Facts on H.P. Acthar® Gel
finance.yahoo.com - May 7 at 8:37 AM
SunTrust Banks Equities Analysts Boost Earnings Estimates for Mallinckrodt (MNK)SunTrust Banks Equities Analysts Boost Earnings Estimates for Mallinckrodt (MNK)
www.americanbankingnews.com - May 7 at 1:56 AM
3 Things In Biotech, May 5: Mallinckrodt Snubbed, Regenxbio Races, Portola Surprises3 Things In Biotech, May 5: Mallinckrodt Snubbed, Regenxbio Races, Portola Surprises
seekingalpha.com - May 6 at 8:43 AM
60 Minutes report to focus on price of Mallinckrodt drug'60 Minutes' report to focus on price of Mallinckrodt drug
www.cnbc.com - May 5 at 8:47 AM
Mallinckrodts (MNK) Market Perform Rating Reaffirmed at Wells FargoMallinckrodt's (MNK) Market Perform Rating Reaffirmed at Wells Fargo
www.americanbankingnews.com - May 4 at 7:03 PM
Mallinckrodt (MNK) Seen as Target of Negative Upcoming 60 Minutes EpisodeMallinckrodt (MNK) Seen as Target of Negative Upcoming 60 Minutes Episode
www.streetinsider.com - May 4 at 5:12 PM
Benzingas Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs DownBenzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down
www.benzinga.com - May 4 at 8:35 AM

SEC Filings

Mallinckrodt (NYSE:MNK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mallinckrodt (NYSE:MNK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mallinckrodt (NYSE MNK) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.